This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Select Medical (SEM) Enters JV to Boost New Jersey Healthcare
by Zacks Equity Research
Select Medical (SEM) collaborates with AtlantiCare to open an inpatient rehabilitation hospital and jointly manage the operations of SEM's outpatient centers across New Jersey.
Select Medical (SEM) Shares Fall 9.6% Since Q3 Earnings Miss
by Zacks Equity Research
Select Medical (SEM) reports improved performance in the Rehabilitation Hospital unit for the third quarter.
Select Medical (SEM) Q3 Earnings Miss Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -52.27% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Tops Q3 Earnings Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 10.08% and 0.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 6.56% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Select Medical (SEM) Plans 3rd Hospital in Central Pennsylvania
by Zacks Equity Research
Select Medical (SEM) joins forces with UPMC to open its third inpatient rehabilitation hospital in Central Pennsylvania to better address the region's post-acute care needs.
Select Medical (SEM) Shares Dip on Q2 Earnings & Revenue Miss
by Zacks Equity Research
Select Medical's (SEM) second-quarter earnings take a hit from escalating expenses and reduced admissions within the Critical Illness Recovery Hospital segment.
Select Medical (SEM) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of -15.69% and 1.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 4.84% and 6.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Select Medical (SEM) Stock is a Strong Buy Now
by Zacks Equity Research
Strategic alliances are bolstering Select Medical's (SEM) growth potential while mitigating the risk factor.
Is Molina Healthcare (MOH) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 Low Price-to-Book Stocks to Add Value to Your Portfolio
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks that have high growth prospects. Vishay Intertechnology (VSH), Group 1 Automotive (GPI), Celestica (CLS), Select Medical Holdings Corporation (SEM) and Signet Jewelers Limited (SIG) are some such stocks.
Select Medical (SEM), Inova Health Form JV in Northern Virginia
by Zacks Equity Research
The JV between Select Medical (SEM) and Inova Health System is expected to own and operate a new 32-bed critical illness recovery facility.
Why You Should Retain Humana (HUM) in Your Portfolio Now
by Zacks Equity Research
Humana's (HUM) strategic acquisitions help it boost its footprint and expand the product portfolio.
Will Mednax's (MD) New Name Pediatrix Medical be Beneficial?
by Zacks Equity Research
Mednax's (MD) name change is expected to take effect following the closing bell on Jul 1, 2022.
UnitedHealth (UNH) Unit Eyes $1.5B EMIS Acquisition in UK
by Zacks Equity Research
UnitedHealth's (UNH) Optum business operates in the United Kingdom for two decades and the acquisition is expected to boost its footprint in the country.
Centene (CNC) Raises 2022 Guidance, Ups Share Buyback Fund
by Zacks Equity Research
Currently, Centene (CNC) has $3.6 billion remaining under its share buyback program.
Is Select Medical (SEM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna (CI) Signs $3.5B Accelerated Share Buyback Agreements
by Zacks Equity Research
Cigna (CI) intends to buy back at least $7 billion worth of its stocks this year alone.
5 Stocks Likely to Give Sweet Surprises on Earnings
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases.
Encompass Health (EHC) Forms JV With NCH Healthcare in Naples
by Zacks Equity Research
The NCH Healthcare System's board grants approval to invest in the joint venture with Encompass Health (EHC).
Encompass Health (EHC) Plans to Distribute Enhabit Shares
by Zacks Equity Research
Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.
Should You Hold On to Teladoc Health (TDOC) Stock for Now?
by Zacks Equity Research
Teladoc Health's (TDOC) cash flows will likely gain from the growing number of visits and memberships.
Humana (HUM) Unveils Transition of Units to CenterWell Brand
by Zacks Equity Research
Humana (HUM) announces the rebranding of its pharmacy divisions to the CenterWell brand, reflecting the rapid expansion initiatives to grow the brand and better serve members.
Select Medical (SEM) Inks JV to Serve Venice and Nearby Areas
by Zacks Equity Research
Select Medical (SEM) teams up with Community Health's arm, ShorePoint Health Venice, for jointly operating a hospital dedicated to serve post-acute care needs of patients.